Highlights

  • Neurotech International (ASX:NTI) received FDA clearance for its Investigational New Drug application for NTI164.
  • The clearance enables a US clinical program focused on pharmacokinetic evaluation of NTI164.
  • NTI164 is being developed for autism spectrum disorder and other neurodevelopmental conditions.
  • Phase 3 Beyond Harmony trial progress remains the key clinical milestone for the company.

Neurotech International (ASX:NTI) has advanced its NTI164 clinical development program after receiving clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug application.

The approval allows the company to progress US clinical activities for its cannabinoid-based therapy candidate and supports its broader strategy of developing a global regulatory pathway.

However, the IND clearance allows clinical testing only and does not represent approval of NTI164 as a commercial treatment.

What Happened?

On 14 July 2026, Neurotech International announced that the FDA had cleared its IND application for NTI164.

The submission included chemistry, Manufacturing and controls (CMC) information, non-clinical data and clinical evidence generated to date.

The clearance allows Neurotech to proceed with a US population pharmacokinetic (PopPK) study designed to assess how NTI164 is absorbed, distributed and cleared within patient populations.

The US program is intended to complement the company’s Australian Phase 3 Beyond Harmony trial in paediatric autism.

Neurotech plans to combine data from both regions into an integrated evidence package to support future regulatory submissions.

Why It Matters

FDA IND clearance is an important regulatory step because it allows a company to conduct human clinical studies in the United States.

For NTI164, the milestone expands Neurotech’s development pathway into the US market, one of the largest healthcare markets globally.

The company is developing NTI164 for autism spectrum disorder, where there are currently limited treatment Options targeting core social and communication symptoms.

However, the IND clearance does not confirm effectiveness or guarantee future regulatory approval. The company must still demonstrate safety and efficacy through larger clinical studies.

The Numbers

NTI164 is described by Neurotech as a proprietary, GMP-grade formulation containing CBDA-rich cannabis extracts and selected minor cannabinoids with low tetrahydrocannabinol (THC).

Previous clinical data came from a randomised controlled autism study involving 54 paediatric participants, including 26 participants receiving NTI164 and 28 receiving placebo.

The study reported a statistically significant improvement on the Clinical Global Impression-Improvement (CGI-I) scale, with a reported treatment effect of -1.42 and a p-value below 0.001.

The study included an eight-week randomised treatment period followed by an eight-week open-label maintenance period.

Neurotech also completed an approximately A$4.5 million Capital raising in August 2026 to support operations through its Phase 3 trial readout.

The Bigger Picture

NTI164 forms part of Neurotech’s broader strategy targeting neurodevelopmental conditions associated with inflammation and immune dysregulation.

The company’s primary focus is autism spectrum disorder, while it has also explored potential applications in Rett syndrome and other neurological conditions.

The Beyond Harmony Phase 3 trial remains the central development program, as it is intended to generate the clinical evidence required for potential regulatory submissions.

The US PopPK study adds additional pharmacokinetic data that may support future submissions across multiple regulatory jurisdictions, including the FDA, European Medicines Agency and Therapeutic Goods Administration.

The Bull Case

The positive case for Neurotech International (ASX:NTI) is based on progressing NTI164 through global clinical development and building a broader regulatory pathway.

FDA IND clearance provides access to US clinical development and allows the company to generate additional data in a major pharmaceutical market.

Previous controlled clinical data provides an initial evidence base, while the Phase 3 Beyond Harmony trial is designed to provide larger-scale validation.

If successful, NTI164 could address an area with limited approved treatment options for autism spectrum disorder.

Risks Investors Should Understand

Neurotech International (ASX:NTI)’s Business faces risks including clinical trial outcomes, regulatory uncertainty, manufacturing requirements and funding pressures.

IND clearance allows clinical testing but does not demonstrate that NTI164 is effective or likely to receive approval.

The earlier autism study involved a relatively small participant group, and results from smaller trials may not be replicated in larger Phase 3 studies.

Cannabinoid-based therapies also require consistent manufacturing standards and ongoing regulatory review.

As a small biotechnology company advancing multiple programs, Neurotech remains dependent on access to capital to complete development activities.

What Comes Next?

The next milestones include commencement of the US PopPK study and continued progress in the Phase 3 Beyond Harmony autism trial.

Investors will monitor enrolment progress, clinical timelines and further regulatory updates.

The company’s ability to combine Australian and US datasets into a global regulatory package will also remain an important focus.

Conclusion

Neurotech International (ASX:NTI) has reached an important regulatory milestone by securing FDA IND clearance for NTI164, allowing the company to begin US clinical development activities.

The clearance expands the company’s global development pathway and supports its ambition to pursue regulatory approvals across multiple markets.

However, the IND represents the beginning of the US clinical process rather than confirmation of treatment effectiveness. The Phase 3 Beyond Harmony trial and future regulatory assessments remain the key determinants of NTI164’s long-term potential.